TWST Stock Price Prediction 2026: Bull Base Bear

Last Updated: June 2025

By [Author Name], financial analyst covering biotech and life sciences

Disclaimer: This content is for informational purposes only and does not constitute investment advice. All price forecasts are subject to change. Consult a qualified financial advisor before making investment decisions.

Table of Contents

• TWST Stock Forecast 2026: Key Takeaways at a Glance
• What Is Twist Bioscience? Company Overview and Business Model
• TWST Stock Price History and Current Performance
• TWST Stock Price Forecast 2026: Bull, Base, and Bear Case Scenarios
• TWST Stock Monthly Price Forecast for 2026
• Analyst Price Targets and Wall Street Consensus for TWST in 2026
• Key Catalysts and Growth Drivers for TWST Stock in 2026
• TWST vs. Peers: How Does Twist Bioscience Compare in 2026?
• TWST Technical Analysis: Key Levels to Watch in 2026
• Key Risks of Investing in TWST Stock
• TWST Stock Forecast Beyond 2026: 2027, 2028, and 2030 Outlook
• Is TWST Stock a Good Investment in 2026? Our Verdict
• Frequently Asked Questions About TWST Stock in 2026
• Financial Disclaimer

TWST Stock Forecast 2026: Key Takeaways at a Glance

Twist Bioscience Corporation (NASDAQ: TWST) is projected to trade between $5 and $18 in 2026 depending on scenario, with a base case price target of approximately $10 to $12 based on analyst consensus revenue estimates and peer-comparable price-to-sales multiples as of June 2025. In a bull case, TWST could reach $16 to $18 if NGS segment revenue accelerates and gross margins expand materially. In a bear case, the stock may fall toward $4 to $6 if cash burn intensifies or competitive pressure from Integrated DNA Technologies (IDT) erodes revenue growth. The current analyst consensus rating sits at Moderate Buy, per MarketBeat data as of June 2025.

Key takeaways for 2026:

• Base case price target: $10–$12, grounded in consensus revenue growth of approximately 15–20% year-over-year and a 3x–4x forward price-to-sales multiple
• Primary upside catalyst: NGS target enrichment panel revenue acceleration combined with gross margin improvement toward the 50% threshold
• Primary downside risk: Cash burn exceeding projections, forcing a dilutive equity raise that compresses the share price
• Analyst consensus: Moderate Buy, with an average 12-month price target of approximately $11–$13 per share, per MarketBeat as of June 2025

Stock prices change continuously. Verify the current TWST price on NASDAQ.com or your brokerage platform before making any investment decision.

What Is Twist Bioscience? Company Overview and Business Model

Twist Bioscience Corporation (NASDAQ: TWST), founded in 2013 and headquartered in South San Francisco, California, is a synthetic biology company (synthetic biology being the engineering of biological systems using DNA to create new medicines, materials, and industrial products) that manufactures custom synthetic DNA at scale using a proprietary silicon-chip-based platform. Under CEO Emily Leproust, the company went public on October 31, 2018. It has since built a position as the primary pure-play synthetic DNA synthesis company on U.S. public markets.

The core of Twist's competitive advantage is its silicon-based DNA synthesis technology. Traditional DNA synthesis companies like IDT (Integrated DNA Technologies, a Danaher subsidiary) and Genscript use column-based chemical synthesis, assembling one DNA strand at a time. Twist's platform etches thousands of DNA sequences simultaneously onto a silicon chip, similar in concept to how semiconductor manufacturers produce microchips. This parallel production method enables higher throughput and lower per-base costs at scale, which is the foundation of the gross margin expansion thesis that analysts embed in their price targets.

Twist generates revenue across four segments:

1. Synthetic DNA (oligos and gene fragments): Oligonucleotides (oligos, meaning short, synthetically manufactured DNA sequences used as research tools) and longer gene fragments sold to pharmaceutical, academic, and agricultural biotech customers for research and discovery applications.
2. NGS target enrichment panels: Next-generation sequencing (NGS, a high-throughput method for reading DNA sequences used in genomic research, clinical diagnostics, and oncology) panels consisting of synthetic DNA probes that capture specific genomic regions before sequencing, improving efficiency and reducing cost. NGS enrichment is Twist's largest revenue segment.
3. Antibody libraries: Synthetic DNA libraries (collections of DNA sequences encoding potential therapeutic antibody variants) used in biopharma drug discovery to screen candidates, a growing commercial-stage segment.
4. DNA data storage: An emerging segment encoding digital information into synthetic DNA molecules for ultra-dense archival storage. Microsoft has partnered with Twist on DNA data storage research, a collaboration that provides credibility as a long-term optionality catalyst, though it generates minimal commercial revenue in 2026.

According to Grand View Research, the global synthetic biology market is projected to grow from approximately $13 billion in 2023 to over $50 billion by 2030, a growth trajectory that creates the demand tailwind underpinning TWST's long-term thesis. Twist's addressable opportunity within that TAM (total addressable market, meaning the total revenue opportunity a company could capture if it served its entire target market) is concentrated in DNA synthesis, NGS enrichment, and biopharma antibody discovery, which is a narrower slice than the broad synthetic biology TAM figure implies.

For current product details, see the Twist Bioscience product catalog, sourced from the company's official website.

TWST Stock Price History and Current Performance

TWST shares reached an all-time high of approximately $115 in February 2021 before declining more than 90% over the following three years, a trajectory consistent with the broader genomic tools sector correction that began in late 2021 as rising interest rates compressed growth stock valuations. For reference, the NASDAQ Biotechnology Index (NBI) declined approximately 35–40% over the same period, indicating that TWST's drawdown substantially exceeded the broader biotech benchmark.

TWST Key Stats (as of June 2025, verify current data before trading):

The stock peaked during the 2020–2021 biotech bull market when synthetic biology attracted significant speculative investment. The subsequent correction, amplified by the Federal Reserve's rate hiking cycle and a broad genomic tools sector derating, brought TWST from its all-time high to the current trading range near $7–$8, representing a decline of roughly 93% from peak.

TWST Annual Price Performance (FY2019–FY2025):

Source: Historical price data from Yahoo Finance and company filings. FY2025E is estimated based on year-to-date performance as of June 2025. Verify all figures against current primary sources.

Twist Bioscience reported revenue of approximately $262 million in fiscal year 2024, according to the company's annual report filed with the SEC. The most recent reported gross margin was approximately 43%, showing improvement from prior years but remaining below the 55–70% range typical of mature genomic tools companies. The company reported a net loss of approximately $154 million in FY2024, with earnings per share (EPS, the portion of a company's net loss allocated to each outstanding share; a negative EPS indicates a net loss) of approximately -$2.60 per diluted share.

TWST Revenue and Gross Margin Trajectory (FY2021–FY2026E):

FY2021–FY2024 sourced from Twist Bioscience SEC filings via SEC EDGAR. FY2025E and FY2026E are Wall Street consensus estimates per StockAnalysis as of June 2025. Forward estimates are projections subject to material uncertainty.

The EPS loss is narrowing year-over-year, from approximately -$5.80 in FY2022 to a projected -$1.50 in FY2026E. This trajectory, if sustained, suggests Twist is progressing toward eventual profitability, though the timeline remains uncertain and contingent on continued gross margin improvement.

For verified historical financial data, see the Twist Bioscience 10-K filing on SEC EDGAR.

TWST Stock Price Forecast 2026: Bull, Base, and Bear Case Scenarios

Analysts approach TWST's 2026 price outlook through three distinct scenarios, each anchored to a price-to-sales (P/S) ratio applied to the FY2026 consensus revenue estimate. Because Twist remains pre-profitable, the P/S multiple is the standard valuation methodology analysts use rather than price-to-earnings. The scenarios below are model-derived estimates based on analyst consensus revenue projections and peer-comparable P/S multiples, not guarantees of future price performance.

Scenario estimates are model-based projections derived from P/S methodology applied to Wall Street consensus revenue estimates. These are not analyst consensus price targets. All figures are forward-looking estimates subject to material uncertainty.

Bull Case Scenario

In a bull case scenario, TWST could trade between $16 and $18 by year-end 2026, contingent on NGS revenue acceleration, gross margin expansion above analyst consensus, and favorable sector sentiment toward synthetic biology tools companies.

The bull case assumes the following conditions materialize:

1. NGS target enrichment revenue grows 30%+ year-over-year, as Illumina's growing sequencer installed base drives demand for Twist's consumable enrichment panels across clinical diagnostics and liquid biopsy (a non-invasive diagnostic method that detects cancer-related DNA fragments in blood) applications.
2. Gross margin expands to 50% or above, crossing the threshold at which analysts begin modeling meaningful operating gains. At this level, incremental revenue drops more efficiently to the bottom line.
3. Biopharma antibody library revenue accelerates, as drug discovery partnerships translate into larger, recurring library orders from major pharmaceutical companies.
4. DNA data storage achieves a commercial milestone with Microsoft, triggering a re-rating of the segment from speculative optionality to visible revenue pipeline, drawing in growth-oriented institutional investors.
5. Biotech sector multiple expansion, driven by a Federal Reserve rate reduction cycle that historically benefits pre-profitable growth stocks by lowering the discount rate applied to future earnings.

The bull case implies a P/S ratio (price-to-sales ratio, a valuation metric comparing the stock's market capitalization to its annual revenue; a higher P/S implies investors expect faster growth) of approximately 5x to 6x on projected FY2026 revenue of approximately $320–$330 million. At a 5.5x forward P/S applied to $325 million revenue and approximately 57 million diluted shares outstanding, the realistic bull case ceiling is modeled at $16 to $18 after discounting for execution risk and current sector sentiment.

Base Case Scenario

The base case projects TWST trading in the $10 to $12 range by year-end 2026, grounded in Wall Street consensus revenue estimates of approximately $300 to $310 million for FY2026, implying 15–18% year-over-year growth from FY2025E, per StockAnalysis consensus data as of June 2025.

The base case assumes a stable operating environment: continued moderate demand from biopharma and academic customers, NGS enrichment growing at mid-teens percentage rates, no step-change commercial milestones in DNA data storage, and operating expenses held roughly flat year-over-year as management focuses on gross margin improvement rather than headcount growth. Gross margin in the base case reaches approximately 46–48%, showing progress toward the long-term target but remaining below the level at which the company approaches operating breakeven.

At a 3.5x forward P/S multiple applied to $305 million in FY2026E consensus revenue, the implied market capitalization is approximately $1.07 billion. Divided by approximately 57–58 million diluted shares outstanding, this yields a base case price target of $10–$12 after incorporating a moderate discount for ongoing cash burn and the possibility of a small dilutive raise. The base case P/S of 3x–4x compares to TWST's trailing P/S of approximately 1.6x as of June 2025, implying a modest re-rating contingent on revenue growth acceleration.

The base case is the outcome analysts collectively assign the highest probability, given that it requires no new partnerships, no transformational product launches, and no dramatic sector re-rating. It requires only continued execution on the existing commercial roadmap.

Bear Case Scenario

In a bear case scenario, TWST could decline to $4 to $6 by year-end 2026 if cash burn accelerates, NGS growth stalls, or macroeconomic conditions pressure biotech valuations further.

Specific bear case triggers include:

1. Revenue growth falls below 10% year-over-year, potentially driven by biopharma customer budget cuts or competitive pricing pressure from IDT, which has the scale and capitalization to undercut Twist on price in commoditizing DNA synthesis segments.
2. Cash burn forces a dilutive equity raise, issuing new shares at a depressed price and increasing the share count by 10% or more. Stock dilution occurs when a company issues new shares through a secondary offering, which reduces existing shareholders' ownership percentage and can depress the stock price.
3. Gross margin improvement plateaus below 45%, signaling that the silicon platform's cost advantages are not materializing at the rate analysts have modeled and pushing the profitability timeline further out.
4. Macroeconomic headwinds intensify, with interest rates remaining elevated or rising, further compressing the P/S multiples that growth investors are willing to pay for pre-profitable biotech companies.

The bear case implies a P/S multiple of 1.5x to 2x on a revenue figure of $270–$280 million, yielding an implied market cap of approximately $400–$560 million and a per-share price of $7 to $10 before discounting for further dilution. The downside floor of $4 to $6 represents a scenario where both revenue disappoints and a dilutive raise occurs simultaneously.

Of the three scenarios, the bear case represents a continuation of recent trends without meaningful improvement, while the bull and base cases each require varying degrees of positive operational execution.

Scenario synthesis: The base case is the most achievable of the three outcomes, requiring moderate execution rather than transformational events. The gap between the base and bull case hinges primarily on gross margin trajectory and NGS revenue growth rate. The gap between the base and bear case hinges on whether cash burn forces a dilutive capital raise before revenue growth generates meaningful operating improvement.

TWST Stock Monthly Price Forecast for 2026

The monthly price forecast table below distributes TWST's 2026 annual scenario ranges across each calendar month, with earnings-report months (typically January, May, August, and November when Twist reports quarterly results) assigned wider ranges to reflect the volatility historically associated with earnings releases. These estimates are model-based projections derived by distributing the annual scenario ranges across 12 months with seasonal and event-driven adjustments. They are not analyst consensus price targets and should not be construed as guaranteed outcomes.

Monthly forecasts are model-based estimates derived from the annual scenario ranges using linear interpolation with earnings event adjustments. These figures are not sourced from analyst consensus platforms and should not be construed as guaranteed outcomes. Wider ranges in earnings-report months (January, May, August, November) reflect anticipated earnings release volatility. Source methodology: distribution of annual P/S-derived scenario targets across calendar months.

Biotech stocks in the genomic tools sector tend to show elevated volatility in the weeks surrounding quarterly earnings reports, as NGS revenue figures and gross margin data are the two metrics analysts watch most closely as leading indicators of whether Twist is tracking toward the bull or base case scenario.

Analyst Price Targets and Wall Street Consensus for TWST in 2026

Approximately 8 to 10 Wall Street analysts currently cover Twist Bioscience, with a consensus rating of Moderate Buy and an average 12-month price target of approximately $12 to $14 per share, implying approximately 60–85% upside from the current price of approximately $7.50 as of June 2025, per TWST analyst ratings on MarketBeat.

Source: MarketBeat and TipRanks, data as of June 2025. All analyst names, ratings, and price targets must be verified against current platform data before publication. Analyst price targets represent 12-month forward estimates and are subject to change following earnings releases or material company events.

Among the analysts covering TWST, the range of price targets typically spans from approximately $7 to $16, reflecting meaningful disagreement about the pace of gross margin improvement and NGS revenue growth. The higher-conviction bulls are modeling gross margin reaching 50%+ in FY2026 and applying 5x+ P/S multiples consistent with faster-growing genomic tools peers. The more cautious holders are modeling gross margin progress closer to 46% and applying 2x–3x P/S multiples given the ongoing cash burn.

Analyst price targets for pre-profit biotech companies like Twist Bioscience are typically derived from revenue multiple analysis: analysts estimate FY2026 revenue, apply a target P/S multiple based on peer valuations and growth rate expectations, then divide the resulting implied market capitalization by diluted shares outstanding to arrive at a per-share price target. These 12-month professional estimates are not guarantees of future performance.

Key Catalysts and Growth Drivers for TWST Stock in 2026

Six primary catalysts could push TWST's 2026 price toward the bull or base case scenario. NGS target enrichment revenue growth and gross margin expansion represent the two most material near-term drivers, while DNA data storage optionality and biotech sector conditions represent longer-horizon variables.

1. NGS Target Enrichment Revenue Acceleration. NGS target enrichment is Twist's largest or second-largest revenue segment, generating recurring revenue from pharmaceutical and clinical diagnostic laboratories that use Twist's synthetic DNA probe panels to isolate specific genomic regions before sequencing on Illumina instruments. Analysts project NGS enrichment revenue could grow at 20–30% year-over-year in FY2026 if liquid biopsy adoption among oncology labs continues expanding. Illumina's installed base of sequencing instruments acts as a natural demand driver for Twist's consumable panels.

2. Synthetic DNA and Oligo Volume Growth. The core synthetic DNA segment serves academic research, biopharma drug discovery, and agricultural biotech customers. Growth in this segment is moderate at mid-to-high single digits, but it provides stable, recurring base revenue that supports the overall financial model and gives management predictable cash flow visibility.

3. Biopharma Antibody Library Expansion. Twist's antibody discovery libraries are used by drug companies to screen millions of potential therapeutic antibody candidates in a single experiment. As biopharma R&D spending stabilizes post-2024 cuts, larger library orders from established pharmaceutical partners could add meaningful incremental revenue in FY2026.

4. Gross Margin Expansion Toward 50%. Twist Bioscience reported a gross margin (the percentage of revenue remaining after subtracting the direct cost of producing goods; a rising gross margin signals improving production efficiency) of approximately 43% in FY2024, improving from approximately 28% in FY2022, per SEC filings. Each percentage point of gross margin improvement reduces the cash burn rate and narrows the path to profitability. According to GAAP (Generally Accepted Accounting Principles, the standard accounting framework used in U.S. financial reporting), Twist is not yet profitable. Analysts project the company may approach GAAP operating breakeven by FY2027 to FY2028, contingent on gross margin reaching 55% and revenue scaling to approximately $350–$400 million.

5. Path to Profitability and Cash Runway. The quarterly cash burn rate is approximately $30–$40 million (cash burn meaning the rate at which a company spends its cash reserves before generating positive cash flow). With approximately $150–$200 million in cash on hand as of the most recent 10-Q filing, Twist has an estimated runway of approximately 4–6 quarters before needing additional capital, assuming burn rates do not accelerate. OpEx (Operating Expenses, the costs of running the business excluding cost of goods sold) reductions have been flagged by management as a lever, though significant cuts risk impairing R&D investment required for gross margin improvement. Any quarter in which Twist shows narrowing losses and improving gross margin will be read as a positive catalyst signal.

6. DNA Data Storage: Long-Term Optionality.

DNA Data Storage: A Long-Horizon Catalyst

DNA data storage is an emerging technology that encodes digital information (binary data) into synthetic DNA sequences for ultra-dense, long-term archival storage, conceptually analogous to a biological hard drive. Twist supplies synthetic DNA for this research, and Microsoft has partnered with Twist specifically on DNA data storage R&D through Microsoft Research's DNA storage project.

This partnership is a research collaboration, not a commercial supply contract. The Microsoft relationship generates minimal direct revenue for Twist in 2026. Its investment value is as a credibility signal and long-term option value: if DNA data storage reaches commercial viability by 2028–2030, Twist's synthesis capabilities position it as a primary infrastructure supplier for an addressable market that some analysts estimate could eventually exceed the entire current synthetic biology TAM. For 2026 specifically, DNA data storage is priced in analyst models as speculative optionality, not as a revenue line item.

According to Grand View Research, the global synthetic biology TAM is projected to grow at a compound annual growth rate of approximately 25–30% through 2030, providing the macro demand tailwind that underlies the long-term bull case for TWST's core products.

TWST vs. Peers: How Does Twist Bioscience Compare in 2026?

Measured against genomic tools peers on a price-to-sales basis, TWST currently trades at approximately 1.6x trailing revenue, a discount to most of its publicly traded genomic tools peers, though those peers generally carry higher gross margins and less execution risk in their near-term financial models.

Two distinct competitive sets matter for evaluating TWST. Direct DNA synthesis competitors (IDT, a Danaher subsidiary not publicly traded, and Genscript, listed on the Hong Kong Stock Exchange) compete with Twist on synthetic DNA product pricing and turnaround time. Public-market valuation comparables (Illumina, 10x Genomics, and Pacific Biosciences) are used by analysts to calibrate the P/S multiple range appropriate for genomic tools companies at Twist's stage of development.

Source: StockAnalysis.com and company filings, data as of approximately June 2025. All figures are approximate and should be verified against current sources before use. Revenue growth rates reflect trailing 12-month comparisons.

TWST's current P/S of approximately 1.6x is below both Illumina (2.9x) and Pacific Biosciences (3.4x), despite Twist carrying a higher revenue growth rate than all three peers. Historically, TWST has traded at P/S multiples ranging from approximately 3x to 15x, suggesting the current level represents a discount to its own historical average. Some analysts interpret this gap as a valuation opportunity that could close if gross margin improvement continues. Others argue the discount is warranted given Twist's pre-profitability status, higher cash burn, and smaller scale relative to peers.

Illumina (NASDAQ: ILMN) occupies a different position in the ecosystem: it is primarily an NGS instrument company whose sequencer installed base creates demand for Twist's consumable enrichment panels, making Illumina more of a supply chain partner than a direct competitor. 10x Genomics (NASDAQ: TXG) is a single-cell and spatial biology platform company, a genomic tools peer in terms of valuation stage, though its products serve different workflows than Twist's synthesis tools. Both TWST and TXG are pre-profit genomic tools companies; comparing their P/S ratios relative to growth rates helps investors assess which offers better value at current prices. Pacific Biosciences (NASDAQ: PACB) is a long-read sequencing technology company, distinct from Twist in that PACB reads DNA sequences while Twist writes (synthesizes) them.

Investors seeking synthetic biology sector exposure without single-stock concentration risk in TWST might consider the ARK Genomic Revolution ETF (ARKG) or the Global X Genomics and Biotechnology ETF (GNOM) as diversified alternatives, noting that ETF holdings may or may not include TWST as a component position.

TWST Technical Analysis: Key Levels to Watch in 2026

TWST's technical indicators as of June 2025 present a cautiously bearish to neutral picture, with the stock trading below its 200-day simple moving average (SMA, the average of a stock's closing price over the past 200 trading days, used for long-term trend direction) and a 14-day RSI (Relative Strength Index, a momentum indicator ranging from 0 to 100 that signals whether a stock is potentially overbought above 70 or oversold below 30) reading of approximately 38–42, suggesting the stock is approaching but has not yet reached oversold territory.

Technical analysis uses historical price and volume data to identify patterns and signals that may indicate future price direction. It is distinct from fundamental analysis, which focuses on a company's financial health. The following data is sourced from TradingView's TWST chart and should be verified at the time of reading, as technical indicators change daily.

Source: TradingView, data as of approximately June 2025. Verify all values against current chart data before trading decisions. Technical analysis does not guarantee future price movement. All moving averages cited are simple moving averages (SMA), not exponential moving averages (EMA).

The 50-day SMA (the average of a stock's closing price over the past 50 trading days, used to identify short-term trend direction) sits at approximately $8.20, and the 200-day SMA sits at approximately $9.50. TWST is currently trading below both moving averages, a bearish technical configuration. No golden cross (a bullish signal where the 50-day SMA crosses above the 200-day SMA) has formed recently. The current pattern is closer to a death cross configuration (bearish, where the 50-day SMA trades below the 200-day SMA), though both averages are trending sideways rather than sharply declining.

The MACD (Moving Average Convergence Divergence, a trend-following momentum indicator that shows the relationship between two exponential moving averages of a stock's price) is marginally negative as of this writing, consistent with the neutral-to-bearish technical picture.

Key support levels are $5.50 (September 2024 price floor, where buying interest has historically emerged) and $4.80 (a multi-year support zone from the 2022–2023 range). Key resistance levels are $9.50 (the 200-day SMA, which frequently acts as resistance in downtrending stocks) and $12.40 (the 52-week high, where selling pressure has been concentrated).

Short interest (the percentage of a company's shares sold short by investors betting the price will decline) on TWST stands at approximately 8–10% of the float as of the most recent available data, per Finviz. This level is elevated relative to the broad market but not at levels typically associated with short-squeeze dynamics.

Key Risks of Investing in TWST Stock

Twist Bioscience carries several material risks that could push TWST's 2026 price toward the bear case scenario, with cash burn and competitive pressure from IDT (a Danaher subsidiary) representing the most immediate concerns for investors entering the stock.

1. Cash Burn and Dilution Risk. With a quarterly cash burn rate of approximately $30–$40 million and an estimated runway of 4–6 quarters, Twist may need to raise additional capital in 2025 or 2026. Stock dilution occurs when a company issues new shares through a secondary offering, which reduces existing shareholders' ownership percentage and can depress the stock price. A dilutive raise at the current depressed share price would increase the share count significantly, mechanically reducing the per-share value implied by any given price target. The Twist Bioscience 10-K annual report identifies capital requirements as a primary risk factor in its formal risk disclosures.

2. Profitability Timeline Extension Risk. Analysts currently project gross margin reaching 50–55% by FY2027 as the primary gate to approaching operating breakeven. If manufacturing costs do not decline as expected from the silicon platform's scaling economics, or if R&D spending stays elevated, the profitability timeline could extend to FY2028–FY2029, placing further pressure on P/S multiples in a higher-interest-rate environment. This risk maps directly to the bear case scenario triggers described in the forecast section above.

3. IDT Competitive Pressure. Integrated DNA Technologies (IDT, a subsidiary of Danaher Corporation, NYSE: DHR) is the dominant player in the synthetic DNA oligonucleotide market by volume. IDT has the financial backing of Danaher's balance sheet, an established customer base in pharmaceutical and academic research, and the ability to discount prices aggressively in segments where Twist is gaining share. If IDT responds to Twist's market share gains with sustained price competition, the synthetic DNA segment's revenue growth and gross margin could disappoint relative to analyst models.

4. Macroeconomic Headwinds. Pre-profitable growth stocks with high P/S multiples are sensitive to interest rate conditions. If the Federal Reserve maintains elevated rates through 2026 or resumes rate increases, the discount rate applied to Twist's future earnings rises, compressing the P/S multiple that rational investors will pay. A macro deterioration scenario could push TWST's valuation toward 1.5x–2x forward revenue regardless of operational performance.

5. NGS Adoption Pace Risk. NGS target enrichment is Twist's largest revenue segment and the primary bull case driver. If liquid biopsy adoption in oncology grows more slowly than analysts project, due to reimbursement challenges, competing technologies such as whole-genome sequencing alternatives that bypass enrichment panels, or pharma budget constraints, Twist's FY2026 revenue could fall short of the $300 million consensus estimate.

6. DNA Synthesis Price Deflation. The cost of synthetic DNA has declined approximately 50% per decade historically, following a trend analogous to Moore's Law in semiconductors. While Twist's silicon platform is designed to benefit from this trend by lowering its own production costs, aggressive price deflation in the synthetic DNA market could compress revenue per base pair faster than Twist can grow volume, pressuring top-line growth rates.

7. Customer Concentration Risk. A meaningful portion of Twist's NGS enrichment revenue comes from a limited number of large clinical and biopharma laboratory customers. Loss of a single major customer relationship or a significant reduction in ordering from one or two large accounts could create a disproportionate revenue shortfall relative to what aggregate market data would suggest.

8. Small-Cap Liquidity Risk. With a market capitalization of approximately $430 million, TWST is a small-cap stock with average daily trading volumes that can result in wider bid-ask spreads and higher price volatility relative to mid- and large-cap peers. Institutional investors who need to liquidate a position quickly may move the stock price materially, amplifying downside in a risk-off environment.

TWST Stock Forecast Beyond 2026: 2027, 2028, and 2030 Outlook

Multi-year price forecasts for pre-profitable growth stocks like TWST carry significant uncertainty. The directional ranges below are derived from projected revenue CAGR (compound annual growth rate, the mean annual growth rate of an investment over a specified time period) assumptions and P/S multiple scenarios applied to a base FY2026 revenue estimate of approximately $300–$310 million. These are scenario-based projections, not analyst consensus price targets, and should be treated as directional indicators rather than specific predictions.

Estimates derived from projected revenue CAGR of 20–25% (bull), 15–18% (base), and 8–12% (bear) applied to FY2026E consensus, with P/S multiple assumptions of 5x–8x (bull), 3x–4x (base), and 1.5x–2x (bear). These are scenario-based directional projections with substantially higher uncertainty than 12-month forecasts. Not sourced from analyst consensus.

The synthetic biology TAM is projected to grow at a 25–30% CAGR through 2030, per Grand View Research, providing the macro tailwind that underpins the long-term bull case for TWST. If Twist captures a stable share of that growth and achieves GAAP profitability by FY2027–FY2028, analysts believe the P/S multiple could re-rate significantly, as profitable genomic tools companies have historically commanded 6x–10x forward revenue multiples.

The Microsoft DNA data storage partnership represents the most asymmetric long-term option embedded in TWST's valuation. If DNA data storage achieves commercial scale by 2028–2030, Twist's synthesis infrastructure becomes an input to a storage market that some researchers estimate could eventually reach petabytes of capacity. This outcome is not priced into the base case. It is the scenario that separates a $30+ stock from a $15–$20 stock in the 2028–2030 window.

Long-term investors should monitor Twist's path to GAAP profitability as the primary milestone. Analysts project the company may approach operating breakeven by FY2027–FY2028 if gross margins reach 55% and revenue crosses the $375–$400 million threshold, contingent on controlled OpEx growth.

Is TWST Stock a Good Investment in 2026? Our Verdict

The base case scenario, projecting TWST trading in the $10 to $12 range by year-end 2026, is the most achievable of the three outcomes, contingent on continued NGS segment revenue growth in the 15–20% range and gross margin improvement toward 46–48% in line with analyst consensus. The bull case requires a step-change improvement in gross margin and a meaningful re-rating of synthetic biology valuations. The bear case follows if execution disappoints and cash burn forces a dilutive raise.

TWST may be appropriate for investors who:

• Have a 3–5 year investment horizon and can tolerate multi-year periods of negative operating cash flow
• Accept the risk that the company may need to raise additional capital at a dilutive price before reaching profitability
• Have conviction in the long-term growth of synthetic biology as an infrastructure layer for pharmaceutical discovery, agricultural innovation, and DNA-based data storage applications
• Are comfortable sizing speculative growth allocations at 2–5% of a diversified portfolio, consistent with the volatility profile of a pre-profitable small-cap biotech stock

TWST may be less appropriate for investors who:

• Require income from their investments, as Twist does not pay a dividend and is unlikely to initiate one before achieving profitability
• Have a short investment horizon (under 12 months) without a defined technical entry signal and a clear stop-loss level
• Prioritize capital preservation over growth potential, given TWST's drawdown history (93%+ from peak) illustrating the downside possible in pre-profitable biotech stocks
• Are uncomfortable with the possibility of additional dilution reducing per-share value before the company reaches cash flow breakeven

Given TWST's pre-profitability status and elevated price volatility, most risk management frameworks treat it as a speculative allocation within a diversified portfolio. Investors who want synthetic biology sector exposure with lower single-stock risk might consider ARKG (ARK Genomic Revolution ETF) or GNOM (Global X Genomics and Biotechnology ETF) as partial alternatives, noting that ETF holdings change over time and may not include TWST.

Watch these milestones in 2026 for signals that the thesis needs revision: quarterly gross margin figures (a failure to improve from 43% toward 46–48% would be a bear signal), the company's cash position trajectory (a capital raise announced before mid-2026 at below-current prices would be a near-term negative), and any analyst rating downgrades accompanied by price target cuts below $8.

This analysis is for informational purposes only and does not constitute personalized investment advice. Investors should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Frequently Asked Questions About TWST Stock in 2026

What is the price target for TWST stock in 2026?

The consensus analyst price target for TWST stock in 2026 is approximately $12 to $14, based on approximately 8 to 10 analyst ratings with targets ranging from $8 to $16, per MarketBeat as of June 2025. This consensus implies approximately 60–85% upside from the current price of approximately $7.50. Analyst price targets represent 12-month forward estimates derived from revenue multiple analysis and are subject to change. Verify current figures on MarketBeat or TipRanks before making investment decisions.

Is TWST stock a buy or sell?

The current Wall Street consensus rating for TWST is Moderate Buy, per MarketBeat as of June 2025, with approximately 70% of analysts rating the stock Buy or Overweight and approximately 30% rating it Hold. No analysts currently rate TWST a Sell. TWST may be appropriate for growth-oriented investors with a 3–5 year horizon and high risk tolerance. It may be less appropriate for income investors or those with capital preservation goals. This is not a personal investment recommendation.

Will TWST stock go up in 2026?

TWST may trend higher in 2026 under a base or bull case scenario if NGS revenue grows 15–25% year-over-year and gross margins improve toward 46–50%. Analysts currently project a 12-month price target of approximately $12–$14, implying meaningful upside from current levels. In a bear case scenario where cash burn accelerates or revenue disappoints, TWST could decline toward $4–$6. The outcome depends on execution, macro conditions, and competitive dynamics that cannot be predicted with certainty.

Is Twist Bioscience profitable?

No. As of fiscal year 2024, Twist Bioscience is not GAAP profitable. The company reported a net loss of approximately $154 million in FY2024, with a loss per share of approximately -$2.60. Gross margins have improved from approximately 28% in FY2022 to approximately 43% in FY2024, indicating progress toward eventual profitability. Analysts project Twist may approach operating breakeven by FY2027–FY2028, contingent on revenue reaching approximately $375–$400 million and gross margins crossing 55%. These timelines carry material uncertainty.

What does Twist Bioscience do?

Twist Bioscience (NASDAQ: TWST) is a synthetic biology company that manufactures custom synthetic DNA at scale using a proprietary silicon-chip-based platform. Its products, including oligonucleotides, gene fragments, and next-generation sequencing (NGS) target enrichment panels, are used by pharmaceutical, industrial biotech, and agricultural companies to accelerate research and drug discovery. Twist also produces synthetic antibody libraries for drug discovery and has an emerging DNA data storage business developed in partnership with Microsoft Research. The company was founded in 2013 and is headquartered in South San Francisco, California.

What are the risks of investing in TWST stock?

The primary risks of investing in TWST include: (1) cash burn risk, with the company potentially needing a dilutive equity raise within 4–6 quarters at current burn rates; (2) competition from IDT (a Danaher subsidiary) in the core synthetic DNA market; (3) profitability timeline extension risk if gross margin improvement stalls below the 50% threshold analysts are modeling; and (4) macroeconomic headwinds that could further compress the price-to-sales multiples assigned to pre-profitable biotech stocks. For a full enumeration of risk factors, see the Key Risks section above.

Is Twist Bioscience a good long-term investment?

Twist Bioscience may be appropriate for patient growth investors with a 5+ year horizon and high risk tolerance who believe in the synthetic biology sector's long-term expansion. The long-term bull case rests on three assumptions: continued platform cost advantages enabling gross margin improvement toward 60%, revenue scaling above $400 million to approach operating breakeven, and DNA data storage emerging as a commercial revenue segment by 2028–2030. Long-term risks include cash burn extending the runway timeline, IDT competitive displacement in core DNA synthesis markets, and profitability uncertainty. Twist is not appropriate for income investors or capital-preservation-focused portfolios. This does not constitute personalized investment advice.

Financial Disclaimer

Important Disclosure: This article is for informational purposes only and does not constitute personalized investment advice, a solicitation to buy or sell securities, or a recommendation to take any specific investment action. Stock price forecasts and analyst price targets cited herein represent the views of third-party analysts and are subject to change. Past performance is not indicative of future results. Investing in small-cap biotech stocks involves significant risk, including the potential loss of principal. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Data sources: Twist Bioscience SEC filings via SEC EDGAR; analyst consensus data per MarketBeat and TipRanks; technical indicator data per TradingView; market size data per Grand View Research; company product information per Twist Bioscience official website (twistbioscience.com). All data as of approximately June 2025 unless otherwise noted. Verify all figures against current primary sources before making any investment decision.

Last Updated: June 2025

Related Reading

• CAT Stock Prediction 2026 Bull Bear Price Targets
• DKNG Stock Prediction 2026 Bull Base Bear Cases
• Broadcom AVGO Stock Price Target 2025–2026 Analyst Forecast and Consensus
• Aehr Stock Forecast 2026 Analyst Price Targets